glp 1 ibs is not just a sensitivity issue—it's an inflammatory condition. For many patients, GLP-1 medications do more than support weight loss. They address one of the root drivers of IBS: inflammation in GLP-1 Series | Part 4
Description
Diabetes Care 44(Supp 1):S40S52 American Diabetes Association (2021) 7
Injectco is awesome

These symptoms are typically mild to moderate in severity and tend to diminish over time as the body adjusts to the medication, particularly when dose escalation follows the recommended gradual schedule
However, our prior work has shown that many patients stop taking GLP-1 RAs prematurely

Recent moves underscore the scale of their commitment: Novo Nordisks oral semaglutide is now FDA-approved and available for obesity treatment in the US
